Cargando…
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series
BACKGROUND: Leukotriene receptor antagonists (LTRAs) are widely used for asthma and allergic rhinitis (AR), but concerns about the risk of neuropsychiatric events (NPEs) have been raised since the first Drug Safety Communication by the US Food and Drug Administration in 2008. This study evaluates th...
Autores principales: | Park, Ji Soo, Cho, Yoo Jung, Yun, Je-Yeon, Lee, Hye Jin, Yu, Jinho, Yang, Hyeon-Jong, Suh, Dong In |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630607/ https://www.ncbi.nlm.nih.gov/pubmed/35595323 http://dx.doi.org/10.1183/13993003.02467-2021 |
Ejemplares similares
-
Use of Leukotriene-Receptor Antagonists During Pregnancy and Risk of Neuropsychiatric Events in Offspring
por: Tsai, Hui-Ju, et al.
Publicado: (2023) -
Leukotriene Antagonists in Dermatology
por: Bubna, Aditya Kumar
Publicado: (2021) -
Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics
por: Park, Jong Sook, et al.
Publicado: (2010) -
Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)()
por: Bian, Sainan, et al.
Publicado: (2021) -
The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study
por: Kang, Sang Oh, et al.
Publicado: (2021)